CheckMate-214
2018
Nivolumab + Ipilimumab in Advanced Renal Cell Carcinoma
In 1,096 patients with untreated advanced clear-cell renal cell carcinoma, nivolumab + ipilimumab improved overall survival in intermediate/poor-risk patients compared with sunitinib.
Result
Efficacy: OS, PFS and ORR (co-primary, intermediate/poor risk)HR 0.63
Below 1 favours nivolumab + ipilimumab, above 1 favours sunitinib.
Also reported: ORR 42% vs 27% (CR 9% vs 1%). 8-yr median OS 46.7 vs 26.0 months (HR 0.69).
- Subtopic
- Advanced RCC
- Design
- Open-label RCT
- Relevance
- Important: one of several pillars.
- Source
- Motzer RJ, et al. N Engl J Med. 2018;378(14):1277-1290.doi 10.1056/NEJMoa1712126
Discussion & critique
First immunotherapy combination in first-line RCC. Benefit concentrated in intermediate/poor-risk disease; IO+TKI combinations are usually preferred for favourable-risk.